The next-generation sequencing (ngs)-based molecular diagnostics market size has grown strongly in recent years. It will grow from $2.26 billion in 2025 to $2.43 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to growth in genetic disorder testing, development of high-throughput sequencing, rising awareness of molecular diagnostics, adoption in clinical labs, technological improvements in sequencing reagents.
The next-generation sequencing (ngs)-based molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to integration of ai and machine learning in diagnostics, expansion of cloud-based genomic platforms, development of portable and point-of-care sequencing devices, rise in personalized medicine applications, collaborations between diagnostics and biotech firms. Major trends in the forecast period include AI-assisted molecular diagnostics, cloud genomic analysis platforms, portable sequencing devices, integration of bioinformatics pipelines, rapid disease marker detection.
The rising incidence of infectious diseases is expected to drive growth in the next-generation sequencing (NGS)-based molecular diagnostics market in the coming years. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that invade and multiply within the body, disrupting normal functions. Increasing global travel and migration contribute to the spread of pathogens across regions and borders, fueling the rise in infectious disease cases. NGS-based molecular diagnostics aids in detecting these diseases by offering comprehensive and precise analysis of pathogens, enabling simultaneous identification of multiple microorganisms, which shortens diagnostic time and improves treatment accuracy and patient care. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased by 10.7%, rising from 4,380 in 2022 to 4,850 in 2023. Consequently, the growing incidence of infectious diseases is propelling the demand for NGS-based molecular diagnostics.
Major companies operating in the next-generation sequencing (NGS)-based molecular diagnostics market are concentrating on developing advanced NGS-based panels to improve the accuracy, accessibility, and efficiency of genetic testing. NGS panels are targeted collections of genes or genomic regions analyzed simultaneously using NGS technology to identify clinically relevant mutations, enabling faster and more precise molecular diagnostics. For example, in April 2024, Pillar Biosciences, a US-based diagnostics company, received FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit, which examines 22 clinically relevant genes in a single multiplex reaction. Designed for use with Illumina’s MiSeq Dx system, the panel offers a sample-to-report time of around 48 hours and can process up to 46 clinical samples per run. OncoReveal CDx includes companion diagnostic claims for KRAS (for EGFR-targeted therapy in colorectal cancer) and EGFR (for TKI therapy in non-small-cell lung cancer), allowing more comprehensive and efficient detection of actionable genomic alterations to enhance clinical decision-making.
In January 2023, QIAGEN NV, a molecular diagnostics and life sciences company based in Germany, acquired Verogen Inc. for an undisclosed sum. This acquisition aims to enhance QIAGEN’s leadership in human identification and forensic genomics by integrating Verogen’s specialized NGS technologies into its broader molecular diagnostics portfolio. This expansion strengthens QIAGEN’s presence in public sector forensics and private sector applications such as genetic genealogy. Verogen Inc. is a US-based company specializing in NGS solutions for forensic genomics.
Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., TATAA Biocenter AB.
North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the NGS-based molecular diagnostics market by raising the cost of imported instruments, sequencing kits, and bioinformatics software. Hospitals, research labs, and diagnostic centers are most affected, particularly in Asia-Pacific and Europe. Segments like high-throughput sequencers and library preparation kits face increased costs. Positive outcomes include promotion of local manufacturing and domestic software development, which enhances supply chain resilience and innovation.
The next-generation sequencing (ngs)-based molecular diagnostics market research report is one of a series of new reports that provides next-generation sequencing (ngs)-based molecular diagnostics market statistics, including next-generation sequencing (ngs)-based molecular diagnostics industry global market size, regional shares, competitors with a next-generation sequencing (ngs)-based molecular diagnostics market share, detailed next-generation sequencing (ngs)-based molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing (ngs)-based molecular diagnostics industry. This next-generation sequencing (ngs)-based molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation sequencing (NGS)-based molecular diagnostics is a technology-driven approach that uses high-throughput sequencing to analyze genetic material with precision and speed. It enables detection of genetic variations, mutations, and disease markers at the molecular level, providing detailed insights into the genetic basis of health and disease. This approach supports precise, data-driven diagnostics by combining sequencing technologies with advanced bioinformatics.
The primary types of NGS-based molecular diagnostics include instruments, reagents and consumables, software and services, panels and assays, and sample preparation kits. NGS instruments are the hardware platforms, such as sequencers and automation workstations, used to perform high-throughput DNA/RNA sequencing. Applications include microbiology, infectious diseases, oncology, genetic testing, and other areas. End users include research centers, academic institutions, hospitals, clinical laboratories, and other organizations.
The next-generation sequencing (NGS)-based molecular diagnostics market includes revenues earned by entities by providing services, such as clinical genomic testing, cancer genomic profiling, infectious disease detection, liquid biopsy testing, and pharmacogenomics testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation sequencing (NGS)-based molecular diagnostics market also includes sales of tumor mutation panels, carrier screening kits, drug response panels, companion diagnostic kits, and whole-genome metagenomics kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The next-generation sequencing (ngs)-based molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to integration of ai and machine learning in diagnostics, expansion of cloud-based genomic platforms, development of portable and point-of-care sequencing devices, rise in personalized medicine applications, collaborations between diagnostics and biotech firms. Major trends in the forecast period include AI-assisted molecular diagnostics, cloud genomic analysis platforms, portable sequencing devices, integration of bioinformatics pipelines, rapid disease marker detection.
The rising incidence of infectious diseases is expected to drive growth in the next-generation sequencing (NGS)-based molecular diagnostics market in the coming years. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that invade and multiply within the body, disrupting normal functions. Increasing global travel and migration contribute to the spread of pathogens across regions and borders, fueling the rise in infectious disease cases. NGS-based molecular diagnostics aids in detecting these diseases by offering comprehensive and precise analysis of pathogens, enabling simultaneous identification of multiple microorganisms, which shortens diagnostic time and improves treatment accuracy and patient care. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased by 10.7%, rising from 4,380 in 2022 to 4,850 in 2023. Consequently, the growing incidence of infectious diseases is propelling the demand for NGS-based molecular diagnostics.
Major companies operating in the next-generation sequencing (NGS)-based molecular diagnostics market are concentrating on developing advanced NGS-based panels to improve the accuracy, accessibility, and efficiency of genetic testing. NGS panels are targeted collections of genes or genomic regions analyzed simultaneously using NGS technology to identify clinically relevant mutations, enabling faster and more precise molecular diagnostics. For example, in April 2024, Pillar Biosciences, a US-based diagnostics company, received FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit, which examines 22 clinically relevant genes in a single multiplex reaction. Designed for use with Illumina’s MiSeq Dx system, the panel offers a sample-to-report time of around 48 hours and can process up to 46 clinical samples per run. OncoReveal CDx includes companion diagnostic claims for KRAS (for EGFR-targeted therapy in colorectal cancer) and EGFR (for TKI therapy in non-small-cell lung cancer), allowing more comprehensive and efficient detection of actionable genomic alterations to enhance clinical decision-making.
In January 2023, QIAGEN NV, a molecular diagnostics and life sciences company based in Germany, acquired Verogen Inc. for an undisclosed sum. This acquisition aims to enhance QIAGEN’s leadership in human identification and forensic genomics by integrating Verogen’s specialized NGS technologies into its broader molecular diagnostics portfolio. This expansion strengthens QIAGEN’s presence in public sector forensics and private sector applications such as genetic genealogy. Verogen Inc. is a US-based company specializing in NGS solutions for forensic genomics.
Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., TATAA Biocenter AB.
North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the NGS-based molecular diagnostics market by raising the cost of imported instruments, sequencing kits, and bioinformatics software. Hospitals, research labs, and diagnostic centers are most affected, particularly in Asia-Pacific and Europe. Segments like high-throughput sequencers and library preparation kits face increased costs. Positive outcomes include promotion of local manufacturing and domestic software development, which enhances supply chain resilience and innovation.
The next-generation sequencing (ngs)-based molecular diagnostics market research report is one of a series of new reports that provides next-generation sequencing (ngs)-based molecular diagnostics market statistics, including next-generation sequencing (ngs)-based molecular diagnostics industry global market size, regional shares, competitors with a next-generation sequencing (ngs)-based molecular diagnostics market share, detailed next-generation sequencing (ngs)-based molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing (ngs)-based molecular diagnostics industry. This next-generation sequencing (ngs)-based molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation sequencing (NGS)-based molecular diagnostics is a technology-driven approach that uses high-throughput sequencing to analyze genetic material with precision and speed. It enables detection of genetic variations, mutations, and disease markers at the molecular level, providing detailed insights into the genetic basis of health and disease. This approach supports precise, data-driven diagnostics by combining sequencing technologies with advanced bioinformatics.
The primary types of NGS-based molecular diagnostics include instruments, reagents and consumables, software and services, panels and assays, and sample preparation kits. NGS instruments are the hardware platforms, such as sequencers and automation workstations, used to perform high-throughput DNA/RNA sequencing. Applications include microbiology, infectious diseases, oncology, genetic testing, and other areas. End users include research centers, academic institutions, hospitals, clinical laboratories, and other organizations.
The next-generation sequencing (NGS)-based molecular diagnostics market includes revenues earned by entities by providing services, such as clinical genomic testing, cancer genomic profiling, infectious disease detection, liquid biopsy testing, and pharmacogenomics testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation sequencing (NGS)-based molecular diagnostics market also includes sales of tumor mutation panels, carrier screening kits, drug response panels, companion diagnostic kits, and whole-genome metagenomics kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Characteristics
3. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Supply Chain Analysis
4. Global Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Trends and Strategies
5. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Analysis of End Use Industries
7. Global Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Segmentation
10. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
12. China Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
13. India Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
14. Japan Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
15. Australia Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
16. Indonesia Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
17. South Korea Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
18. Taiwan Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
19. South East Asia Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
20. Western Europe Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
21. UK Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
22. Germany Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
23. France Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
24. Italy Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
25. Spain Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
26. Eastern Europe Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
27. Russia Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
28. North America Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
29. USA Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
30. Canada Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
31. South America Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
32. Brazil Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
33. Middle East Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
34. Africa Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market
36. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Competitive Landscape and Company Profiles
37. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market Other Major and Innovative Companies
40. Next-Generation Sequencing (Ngs)-Based Molecular Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses next-generation sequencing (ngs)-based molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for next-generation sequencing (ngs)-based molecular diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation sequencing (ngs)-based molecular diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Instruments; Reagents And Consumables; Software And Services; Panels And Assays; Sample Preparation Kits2) By Application: Microbiology; Infectious Diseases; Oncology; Genetic Tests; Other Applications
3) By End User: Research Centers And Academics; Hospitals And Clinical Laboratories; Other End Users
Subsegments:
1) By Instruments: Benchtop Sequencers; High-Throughput Sequencers; Portable Or Handheld Sequencers; Clinical Or Diagnostic Sequencers; Automated Library Preparation Systems; Data Analysis And Bioinformatics Hardware2) By Reagents And Consumables: Sequencing Reagents And Kits; Library Preparation Reagents; Target Enrichment Reagents; Amplification Reagents; Sequencing Flow Cells And Chips; Deoxyribonucleic Acid (DNA) Or Ribonucleic Acid (RNA) Extraction Reagents; Quality Control Reagents
3) By Software And Services: Data Analysis Software; Bioinformatics Pipelines; Cloud-Based Genomic Platforms; Clinical Interpretation Tools; Data Storage And Management Services; Custom Bioinformatics Services; Genomic Database Services
4) By Panels And Assays: Oncology Panels; Infectious Disease Panels; Carrier Screening Panels; Reproductive Health Panels; Rare Disease Or Genetic Disorder Panels; Pharmacogenomics Panels; Whole-Exome Or Whole-Genome Assays
5) By Sample Preparation Kits: Deoxyribonucleic Acid (DNA) Extraction Kits; Ribonucleic Acid (RNA) Extraction Kits; Library Preparation Kits; Target Enrichment Kits; Amplification And Cleanup Kits; Single-Cell Preparation Kits; Low-Input Or Degraded Sample Kits
Companies Mentioned: Thermo Fisher Scientific; Siemens Healthineers AG; Agilent Technologies Inc.; Illumina Inc.; PerkinElmer Inc.; Bio-Rad Laboratories Inc.; Qiagen N.V.; Amoy Diagnostics Co. Ltd.; Tempus Labs Inc.; Myriad Genetics Inc.; Epigenomics AG; Precision for Medicine Inc.; Invitae Corporation; NeoGenomics Laboratories Inc.; Guardant Health Inc.; Caris Life Sciences Inc.; Foundation Medicine Inc.; Oxford Nanopore Technologies Ltd.; Freenome Inc.; Burning Rock Biotech; Element Biosciences Inc.; Asuragen Inc.; Bionano Genomics Inc.; Genomic Health Inc.; TATAA Biocenter AB
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Next-Generation Sequencing (NGS)-Based Molecular Diagnostics market report include:- Thermo Fisher Scientific
- Siemens Healthineers AG
- Agilent Technologies Inc.
- Illumina Inc.
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- Qiagen N.V.
- Amoy Diagnostics Co. Ltd.
- Tempus Labs Inc.
- Myriad Genetics Inc.
- Epigenomics AG
- Precision for Medicine Inc.
- Invitae Corporation
- NeoGenomics Laboratories Inc.
- Guardant Health Inc.
- Caris Life Sciences Inc.
- Foundation Medicine Inc.
- Oxford Nanopore Technologies Ltd.
- Freenome Inc.
- Burning Rock Biotech
- Element Biosciences Inc.
- Asuragen Inc.
- Bionano Genomics Inc.
- Genomic Health Inc.
- TATAA Biocenter AB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.43 Billion |
| Forecasted Market Value ( USD | $ 3.23 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
